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Advances in understanding basic developmental and physiological processes often 
have direct relevance to human disease. They provide insights into pathogenic mecha-
nisms and reveal new pathways that can be exploited in diagnosis and the development 
of therapeutics.Introduction
Investigators studying the nervous 
system form two groups: those 
striving to understand neuronal 
differentiation, connectivity, and 
function (basic scientists), and 
those studying neurological disor-
ders, disease pathogenesis, and 
therapeutics (clinicians and clini-
cal researchers). With the identi-
fication of the molecular bases of 
several neurological disorders, the 
two principal challenges are the 
proper allocation of investments 
in basic and clinical research and 
acceleration of the discovery and 
development of therapies. Bearing 
these two challenges in mind, we 
take a historical perspective in this 
Essay and analyze three “success 
stories” in the field of neurological 
disease research.
These examples share two key 
ingredients. First, basic research 
contributions advance the under-
standing of disease mechanisms 
and provide a rich source of path-
ways for therapeutic targeting. 
This demonstrates that invest-
ment in basic research provides 
substantial clinical returns. Sec-
ond, the astute observations of 
clinicians are essential for placing 
basic research findings into the 
appropriate clinical framework. 
These examples clearly reveal that 
basic research provides the seeds 
for clinical discoveries and that 
only through the union of basic 
research and clinical medicine can 
we hope to overcome the chal-
lenges inherent in diagnosing and 
curing neurological disease.Marrying Basic Research to 
 Clinical Intervention: Parkinsonism
Parkinson’s disease (PD) is an idio-
pathic disorder that is the second 
most common cause of neurode-
generation, afflicting more than 1 
million Americans over the age of 50. 
The scholarly documentation of PD’s 
clinical hallmarks (bradykinesia, pos-
tural instability, rigidity, and tremor) 
by the physician James Parkinson in 
1817 brought PD to medical attention. 
In addition to physical impairments, 
affected individuals also have a high 
rate of depression and an increased 
risk of death.
The first breakthrough in PD 
research came in the late 1950s 
through the contributions of Arvid 
Carlsson and coworkers. This group 
demonstrated that dopamine was 
present in the mammalian brain and 
proposed that it might be acting as 
a neurotransmitter (Carlsson et al., 
1958). They also showed that rab-
bits given reserpine, a dopamine-
depleting agent, experienced rigid-
ity that could be reversed through 
the administration of L-DOPA, the 
immediate precursor to dopamine. 
These advances led astute clinical 
pathologists to discover that dopa-
mine was depleted in the substantia 
nigra pars compacta (SNpc) of post-
mortem brain tissue from patients 
with PD, and led clinicians to the 
first trial of L-DOPA in PD patients. 
For clinical neurology, this is per-
haps the single best example of how 
basic research inspired drug treat-
ment of a disorder. Forty-five years 
later, L-DOPA remains a mainstay of 
PD treatment.Cell 12The correlation of dopaminergic 
cell loss in the SNpc with the symp-
toms of PD allowed symptomatic 
relief, but did not identify the patho-
genic mechanisms that cause the 
disease. The first step toward under-
standing these mechanisms came 
from a chance clinical observation 
by practicing neurologists (Langs-
ton et al., 1983). They reported that 
a small group of intravenous drug 
users in California developed an 
acute but permanent Parkinsonian 
syndrome after using a meperidine 
analog tainted with the synthetic 
byproduct MPTP. Investigations in 
animal models revealed that MPTP 
is toxic to nigral dopaminergic neu-
rons because its reactive metabolite, 
MPP+, is selective for the dopamine 
transporter and inhibits mitochon-
drial complex I. Animal models also 
revealed that other complex I inhibi-
tors, such as the pesticides paraquat 
and rotenone, recapitulated not only 
the symptoms of Parkinsonism but 
also selective neurodegeneration of 
the SNpc and the development of 
cellular inclusions containing ubiqui-
tin and α-synuclein that mimic Lewy 
bodies (the pathological hallmarks of 
PD). This information prompted cli-
nicians to evaluate postmortem PD 
brain tissue for evidence of oxidative 
damage (which they found), and to 
discover that patients with sporadic 
PD have impaired complex I activ-
ity in peripheral tissues, suggesting 
a more widespread defect in oxida-
tive mitochondrial function. These 
data support the conclusion that 
mitochondrial dysfunction contrib-
utes to the pathogenesis of PD, and 6, July 14, 2006 ©2006 Elsevier Inc. 11
highlight the power of a combined 
approach where clinical observa-
tions and bench research inform one 
another.
Although the majority of PD cases 
occur sporadically, PD also runs in 
families. Ascertainment of such fami-
lies by dedicated clinical neurologists 
has provided the key resource for the 
identification of genes that cause PD 
(α-synuclein, DJ-1, lRRK2, paR-
Kin, and pinK1) and the identification 
of other loci whose relationship to PD 
is less clear. Although mutations in 
these genes are associated with less 
than 5% of the total number of PD 
cases, the linkage of α-synuclein 
and lRRK2 to sporadic disease rein-
forces the idea that understanding 
familial PD will inform us about the 
sporadic form of the disease.
Animal models harboring engi-
neered mutations in the PD-associ-
ated genes α-synuclein and parkin 
have yielded valuable insights into 
the pathogenic mechanism of PD 
(Moore et al., 2005). Overexpres-
sion of normal α-synuclein in fruit 
flies leads to selective degeneration 
of dopaminergic neurons (Feany and 
Bender, 2000), a finding consistent 
with the discovery that duplications 
and triplications of the α-synuclein 
locus in human PD pedigrees cause 
PD (Singleton et al., 2003). Recent 
observations from the fly model show 
that phosphorylation of wild-type α-
synuclein decreases the solubility of 
the protein and promotes inclusion 
body formation (Chen and Feany, 
2005). Two human mutations in α-
synuclein (A53T and A30P) cause 
increased aberrant phosphorylation 
of the protein and decreased inclu-
sion body formation. These data sug-
gest that protein aggregate formation 
may be a protective response of the 
cell that is sensitive to phosphoryla-
tion state. Mice lacking α-synuclein 
are protected from MPTP-mediated 
SNpc degeneration, suggesting that 
α-synuclein may mediate mitochon-
drial dysfunction (Dauer et al., 2002). 
Finally, mice lacking both α- and 
β-synuclein demonstrate no obvi-
ous deleterious effects, suggesting 
that pharmacological strategies that 
decrease expression of α-synuclein 12 Cell 126, July 14, 2006 ©2006 Elseviermight be both beneficial and well 
tolerated in humans (Chandra et al., 
2004).
Parkin acts as an E3 ubiquitin pro-
tein ligase, transferring ubiquitin resi-
dues to proteins and targeting them 
for destruction. Elevated levels of 
parkin protect neurons from the tox-
icity of α-synuclein and rescue the 
pinK1-deficient phenotype in fruit 
flies, suggesting that these PD-asso-
ciated proteins function in a common 
pathway. Furthermore, mutation of 
parkin in Drosophila leads to mito-
chondrial swelling and subsequent 
apoptosis of muscle cells. These 
findings place parkin in a pathogenic 
pathway that involves mitochondrial 
dysfunction, which may be a key 
event in the sporadic form of PD.
Many questions remain to be 
answered. How do environmental 
factors affect the products of genes 
associated with PD? What is the 
underlying cause of Parkinsonism in 
people without known gene muta-
tions? And, most importantly, how do 
we modify or stop the relentless pro-
gression of PD? The path has been 
charted for researchers to tackle 
these questions, providing hope that 
new treatments will be developed for 
this devastating disease.
Holoprosencephaly, Cancer and 
the SHH Signaling Pathway
Holoprosencephaly (HPE) is the 
most common major malformation 
of human cerebral development, 
occurring in 1 in 8300 live births and 
up to 1 in 250 pregnancies. The dis-
order results from the failure of the 
developing forebrain to form paired 
cerebral hemispheres; other mid-
line central nervous system (CNS) 
structures such as the basal ganglia, 
hypothalamus, pituitary, and thala-
mus can also be involved. The clini-
cal reality is that HPE rarely occurs 
as an isolated entity. Roughly 80% 
of cases are associated with vary-
ing degrees of facial malformations 
ranging from mild (the presence of a 
single upper central incisor) to severe 
(cyclopia with a proboscis). HPE can 
also be part of larger genetic syn-
dromes with more varied associated 
phenotypes. Inc.Although the majority of HPE 
cases are sporadic, several clues 
point to a strong genetic contribution 
to the disorder. Chromosomal abnor-
malities account for up to 50% of live 
birth HPE cases, particularly when 
extracephalic findings are pres-
ent. Other cases come from pedi-
grees with affected twins or family 
members from multiple generations 
with normal chromosomes. Careful 
phenotypic cataloging of multiple 
families by many clinicians led to the 
identification of 12 loci associated 
with HPE.
The first breakthrough in uncov-
ering the gene defects responsible 
for HPE came with the discovery 
that disruption of the mouse sonic 
hedgehog (shh) gene resulted in an 
HPE phenotype complete with mid-
line facial defects including cyclopia 
(Chiang et al., 1996). Armed with this 
knowledge, Maximillian Muenke’s 
group demonstrated that mutations 
in sHH were present in several fami-
lies with HPE (Roessler et al., 1996). 
But why would this gene cause HPE, 
and how would its identification shed 
light on the developmental mecha-
nisms responsible for the disorder? 
Over fifteen years of work character-
izing Drosophila development could 
now be brought to bear on a clinical 
problem. In Drosophila, Hedgehog 
(Hh) codes for a secreted protein 
that directs segmentation and the 
development of multiple fly organ 
systems, and its signaling pathway 
has been well characterized (see 
Figure 1). Mammalian homologs of 
Hh (such as shh) and other pathway 
components play important roles 
in mammalian development. The 
observation that shh is expressed in 
the developing vertebrate notochord 
and ventral neural tube led to the dis-
covery of its importance in patterning 
of the CNS midline and, ultimately, 
to its link to HPE in shh-deficient 
mice. Evaluation of human muta-
tions in other pathway proteins led 
to the identification of pTcH1 (one 
of two mammalian ptc homologs) 
as the gene associated with HPE7 
(Ming et al., 2002) and Gli2, one of 
three mammalian cubitus interrup-
tus homologs, as the gene associ-
ated with the syndrome of 
pituitary anomalies with holo-
prosencephaly-like features 
(Roessler et al., 2003). These 
are elegant examples of how 
the basic understanding of a 
developmental pathway can 
have unexpected relevance 
to a clinical disease.
Further insights into the 
pathogenesis of HPE came 
from synergy between basic 
and clinical research involv-
ing the rare Smith-Lemli-Opitz 
syndrome (SLOS) (Smith et 
al., 1964). SLOS is an autoso-
mal recessive disease charac-
terized by mental retardation, 
polydactyly, genital malforma-
tions, cleft lip/palate, and poor 
growth. It is caused by muta-
tions in the gene encoding 3β-
hydroxysterol-∆7-reductase 
that result in up to a 2000-fold 
increase in levels of 7-dehy-
drocholesterol, the immediate 
precursor of cholesterol (see 
Figure 1). This information set 
the stage for the discovery of 
an unexpected link between 
the pathogenesis of SLOS and 
HPE. Philip Beachy’s lab dem-
onstrated that Hh proteins 
require a cholesterol adduct 
for proper extracellular local-
ization and function (Porter et 
al., 1996). In addition, terato-
gens that cause HPE, such 
as cyclopamine and jervine, 
disrupt transduction of the Hh sig-
nal in target tissues. These findings 
prompted an unbiased screening 
of HPE patients for abnormalities of 
cholesterol metabolism, uncovering 
a small number that also had undi-
agnosed SLOS (Kelley et al., 1996). 
The careful clinical evaluation of a 
rare disease combined with a funda-
mental understanding of a basic bio-
chemical pathway led to an expansion 
of a clinical spectrum, illustrating how 
information can go from the clinic to 
the bench and back again.
In addition to its detrimental effects 
on normal morphogenesis, dysregu-
lation of the SHH signaling path-
way can lead to the development of 
medulloblastoma, the most common 
malignant brain tumor of childhood 
(see Figure 1). Medulloblastomas 
typically arise in the cerebellum, 
most likely from the external granular 
layer, a secondary proliferative neu-
roepithelium where cell division and 
maturation are regulated by SHH. 
Dysregulated activity of the path-
way through inactivation of PTCH (or 
SUFU) or activation of GLI can lead 
to malignant transformation of exter-
nal granule layer cells. Mutations in 
these genes, along with activating 
mutations in smoothened (SMO), are 
also associated with other cancers 
such as basal cell carcinoma and 
rhabdomyosarcoma.
The mainstays of treatment for 
medulloblastoma are chemotherapy, 
radiation therapy, and surgery, 
all of which have long-term 
adverse effects on growth 
and development. By using 
specific inhibitors of the SHH 
pathway, two groups were 
able to change the growth 
dynamics of malignant cells 
in vitro and to treat medul-
loblastomas in living animals 
(Berman et al., 2002; Romer 
et al., 2004). In addition to 
being an effective therapeutic 
strategy, SHH pathway inhibi-
tors like cyclopamine selec-
tively target malignant cells 
and have little effect on nor-
mal tissues, potentially offer-
ing a therapeutic avenue that 
can minimize toxicity without 
compromising effectiveness 
of treatment.
Putting a Tone Back in 
Deaf Ears with Atoh1
Identification of the molecule, 
Atonal, that drives internal 
mechanoreceptor (proprio-
ceptor) development in Dro-
sophila has provided remark-
able insights into hearing loss 
in humans. Mechanoreception 
is the detection of tension, 
pressure, and displacement. 
The canonical mechanorecep-
tor in vertebrates and inver-
tebrates consists of a spe-
cialized, ciliated cell that can 
detect movement and vibra-
tion (see Figure 2). Modifications to 
this basic scheme allow organisms to 
detect movement against their body 
surface, hear sounds, and determine 
their position in space. In Drosophila, 
the chordotonal organs (CHOs) act as 
proprioceptors in the fly cuticle; John-
ston’s organ, an array of CHOs found 
in the second antennal segment, is 
important in hearing and detects the 
fly’s position with respect to gravity. 
CHOs are composed of a single neu-
ron surrounded by multiple support 
cells (see Figure 2). The sensory neu-
ron is specified by expression of the 
atonal gene, which encodes a basic 
helix-loop-helix transcription factor 
that is both necessary and sufficient 
for CHO specification.
Figure 1. The Mammalian Hedgehog Signaling 
 Pathway and Human Disease
Sonic hedgehog (SHH) binds to its receptor patched (PTCH), 
releasing inhibition of smoothened (SMO). Cholesterol modifi-
cation (blue circle) of SHH is necessary for the proper localiza-
tion and signaling of SHH. Activated SMO inhibits suppressor 
of fused (SUFU), which releases inhibition of gliomas-asso-
ciated oncogene homolog (GLI). GLI is a transcription factor 
that drives SHH-induced gene expression. Holoprosencephaly 
(HPE)-related conditions resulting from mutations in pathway 
components are pink; cancers caused by pathway mutations 
are purple. 7-DHCR, 3β-hydroxysterol-∆7-reductase; BCNS, 
basal cell nevus syndrome; PAHPL, pituitary anomalies with 
holoprosencephaly-like features; SLOS, Smith-Lemli-Opitz 
Syndrome.Cell 126, July 14, 2006 ©2006 Elsevier Inc. 13
Figure 2. Atonal/Atoh1 and Development of Proprioceptive and Auditory Tissue
Shown in orange are cells and tissues of the proprioceptive and auditory systems whose devel-
opment depends on expression of the atonal gene in flies and the atoh1 gene in mammals. In the 
fly, only development of peripheral sensory organs is atonal-dependent; in mammals, develop-
ment of both central and peripheral structures is atoh1-dependent.The importance of atonal in the 
development of the proprioceptive 
system in the fruit fly prompted a 
search for homologous genes in 
the mouse, leading to the identi-
fication of five genes with vary-
ing expression patterns. atoh1 
(Math1) is expressed throughout 
the embryonic dorsal neural tube, 
which gives rise to the central sen-
sory system, from the rostral hind-
brain to the caudal spinal cord. 
This expression pattern, coupled 
with the uncoordinated phenotype 
of viable atonal-deficient flies, led 
our lab to engineer atoh1-deficient 
mice to determine whether the 
gene played a role in the develop-
ment of the mammalian proprio-
ceptive system.14 Cell 126, July 14, 2006 ©2006 Elsevier Like atonal-deficient flies, atoh1-
deficient mice have disrupted pro-
prioceptive and auditory systems. 
Multiple components of the central 
spinocerebellar system (granule and 
deep nuclear neurons of the cer-
ebellum, multiple brainstem nuclei, 
and dorsal commissural neurons of 
the spinal cord), which coordinates 
movement and motor learning by 
integrating proprioceptive and ves-
tibular inputs, express atoh1 and 
are missing in atoh1-deficient mice 
(see Figure 2) (Wang et al., 2005). In 
the mouse, Merkel cells of the skin 
mediate pressure and touch sensa-
tion and express atoh1, although 
the effects of deleting this gene on 
this cell population are not clear. In 
the auditory system, neurons in the Inc.cochlear nuclei and hair cells of the 
inner ear are absent in atoh1-defi-
cient mice.
This last observation has particu-
lar relevance for clinical medicine, as 
hearing loss is a common and dev-
astating form of sensory impairment. 
Roughly 10% of the general popula-
tion (about 21 million people in the 
United States alone) has hearing 
loss great enough to impair commu-
nication; this proportion increases to 
50% by age 80. Notably, about 80% 
of sensorineural hearing loss cases 
in adults occur secondary to loss of 
sensory hair cells in the inner ear. If, 
as in flies, atoh1 is sufficient to direct 
the specification of hair cell precur-
sors, it might be possible to repopu-
late deaf ears with a new comple-
ment of hair cells and thereby restore 
hearing.
To test this hypothesis, nor-
mal cochlea and utricles from the 
inner ear of early postnatal rats 
were grown in tissue culture and 
transfected with atoh1, resulting 
in the conversion of sensory epi-
thelial cells into extra hair cells in 
the absence of cell division (Zheng 
and Gao, 2000). The human atoh1 
homolog, Hath1, produced similar 
results, and utricles depleted of 
hair cells by ototoxic drug applica-
tion also responded to atoh1 treat-
ment. Most importantly, a recent 
study demonstrated an improve-
ment in auditory brainstem evoked 
responses to sound in guinea pigs 
treated by injecting adenovirus 
expressing atoh1 into their cochlea 
(Izumikawa et al., 2005). This rep-
resents the first evidence of func-
tional recovery in a mammal after 
the onset of deafness.
Although challenges remain re-
garding gene therapy delivery sys-
tems in the primate and the potential 
need for concomitant regeneration 
of auditory nerve fibers in addition to 
hair cells, this is an exciting develop-
ment that holds great promise for the 
future. As the functions of develop-
mentally important genes are charac-
terized, one hopes that regeneration 
of other sensory systems such as vi-
sion and touch will also become a vi-
able reality in the future.
Conclusion
Although resources are limited, it is 
essential that we maintain healthy 
funding for basic science as part 
of our national approach to treat-
ing human disease. In the course 
of their studies, basic scientists 
need to actively seek connections 
to human conditions to ensure that 
the relevance of their research is 
not overlooked. To help direct this 
endeavor, we must recognize the 
value of crosstalk with the clinical 
world and involve clinicians so that 
basic science advances can be put 
into a meaningful clinical framework. 
This means that the clinical environ-
ment must be receptive and must 
enable physicians to take the time to 
recognize and report unusual clinical 
observations and to ponder discov-
eries from the basic research world. 
Without these key ingredients, we will 
be hard-pressed to meet the chal-
lenges presented by human disease. 
It is only by the continued marriage 
of bench research and medicine and 
open communication between the 
two disciplines that we can hope to 
uncover ways to halt the progression 
or reverse the effects of neurological 
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